<b>Effects of ARV-110 in the liver proteome in DHT-treated mice.</b>
收藏资源简介：
Supplementary Data for:<b>Androgen Receptor PROTAC ARV-110 Ameliorates Metabolic Complications in a Mouse Model of Polycystic Ovary Syndrome</b>Jelina Basnet<sup>1,3,4,5</sup>, Samar Rezq<sup>1,3,4,5</sup>, Alexandra M. Huffman<sup>1,3,4,5</sup>, Tolulope E. Asala<sup>1,3</sup>, Licy L. Yanes Cardozo<sup>1,2,3,4,5,6</sup>, Damian G. Romero<sup>1,3,4,5</sup>Departments of <sup>1</sup>Pharmacology and Toxicology, and <sup>2</sup>Medicine (Endocrinology), <sup>3</sup>Mississippi Center of Excellence in Perinatal Research, <sup>4</sup>Women’s Health Research Center, <sup>5</sup>Cardiovascular-Renal Research Center, University of Mississippi Medical Center, Jackson, Mississippi, USA<b>Effects of ARV-110 in the liver proteome in DHT-treated mice.</b> Mice were treated with dihydrotestosterone (DHT) or control (CON) for 12 weeks. During the last 8 weeks, mice were additionally treated with low-dose ARV-110 (ARV-L, 1 mg/kg/day), high-dose ARV-110 (ARV-H, 10 mg/kg/day), or vehicle (VEH).<br>
